Results from the FIBRONEER-ILD trial showed nerandomilast significantly slowed lung function decline in patients with PPF compared with placebo. The Food and Drug Administration (FDA) has expanded the ...
“Progressive pulmonary fibrosis is linked to underlying clinical ILD diagnoses including autoimmune ILDs – which can be caused by disorders like rheumatoid arthritis or systemic sclerosis – as well as ...
Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...
/PRNewswire/ -- Boehringer Ingelheim's JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results